title: [Thiazolidine, thiazolidinediones, TZD].
abstract: In addition to a good efficacy to lower blood glucose without hypoglycemia, thiazolidinediones(TZDs) have been proved to have the effects to increase plasma adiponectin, and actually decrease the cardiovascular events in several randomized clinical trials, while some adverse effects have also been demonstrated such as increase of heart failure and born fracture, and fear of bladder cancer. Since TZDs could intervene the pathogenesis of adipocytes' hypertrophy and inflammation in adipose tissue, atherosclerotic lesions and liver by modulating PPARγ of adipocytes and macrophages, TZDs are still considered at the special position among other diabetic drugs, and require further evidence for their efficacy and safety.
authors: Masatoshi
authors: M
authors: Kobayashi
authors: Kohjiro
authors: K
authors: Ueki
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D045162:Thiazolidinediones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D053778:Thiazolidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D045162:Thiazolidinediones; D053778:Thiazolidines